Abstract
Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Marcel D Posthumus, Pieter C Limburg, Johanna Westra, Miek A van Leeuwen and Martin H van Rijswijk
The Journal of Rheumatology May 2002, 29 (5) 883-889;
Marcel D Posthumus
Pieter C Limburg
Johanna Westra
Miek A van Leeuwen
In this issue
Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Marcel D Posthumus, Pieter C Limburg, Johanna Westra, Miek A van Leeuwen, Martin H van Rijswijk
The Journal of Rheumatology May 2002, 29 (5) 883-889;
Serum matrix metalloproteinase 3 levels during treatment with sulfasalazine or combination of methotrexate and sulfasalazine in patients with early rheumatoid arthritis.
Marcel D Posthumus, Pieter C Limburg, Johanna Westra, Miek A van Leeuwen, Martin H van Rijswijk
The Journal of Rheumatology May 2002, 29 (5) 883-889;